Latuda and Agranulocytosis - a phase IV clinical study of FDA data

Summary:

Agranulocytosis is reported as a side effect among people who take Latuda (lurasidone hydrochloride), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Clozaril, and have Schizophrenia.

The phase IV clinical study analyzes which people have Agranulocytosis when taking Latuda. It is created by eHealthMe based on reports of 20,677 people who have side effects when taking Latuda from the FDA, and is updated regularly.

What is Latuda?

Latuda has active ingredients of lurasidone hydrochloride. It is often used in bipolar disorder. eHealthMe is studying from 21,543 Latuda users. Check the latest studies of Latuda.

What is Agranulocytosis?

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection) is found to be associated with 2,327 drugs and 3,591 conditions by eHealthMe. Check the latest studies of Agranulocytosis.

On Jul, 08, 2026

20,677 people reported to have side effects when taking Latuda.
Among them, 74 people (0.36%) have Agranulocytosis.

Among these 74 people:

How long have people been on Latuda when they have Agranulocytosis? *

What is the gender of people who have Agranulocytosis when taking Latuda? *

female: 49.21 %
male: 50.79 %

What is the age of people who have Agranulocytosis when taking Latuda? *

What are other drugs people take besides Latuda? *

What are other side effects people have besides Agranulocytosis? *

Leukopenia (less number of white blood cells in blood): 28 people, 37.84%
Psychotic Disorder: 9 people, 12.16%
White Blood Cell Count Decreased: 8 people, 10.81%
Hypersexuality: 7 people, 9.46%
Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 5 people, 6.76%
Rashes (redness): 5 people, 6.76%
Indigestion: 3 people, 4.05%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 3 people, 4.05%
Iron Deficiency: 3 people, 4.05%
Obsessive-Compulsive Disorder (an anxiety disorder characterized by intrusive thoughts that produce uneasiness, apprehension, fear, or worry;): 3 people, 4.05%

What are the existing conditions these people have? *

Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 31 people, 41.89%
Schizoaffective Disorder (a mental disorder characterized by disordered thought): 9 people, 12.16%
Hypersexuality: 7 people, 9.46%
Restless Leg Syndrome (a powerful urge to move your legs): 5 people, 6.76%
Myoclonus (a brief, involuntary twitching of a muscle or a group of muscles): 4 people, 5.41%
Psychotic Disorder: 4 people, 5.41%
Agitation (state of anxiety or nervous excitement): 4 people, 5.41%
Obsessive-Compulsive Disorder (an anxiety disorder characterized by intrusive thoughts that produce uneasiness, apprehension, fear, or worry;): 3 people, 4.05%
Schizophrenia, Paranoid Type (delusions and auditory hallucinations but relatively normal intellectual functioning and expression of affect): 2 people, 2.70%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 2 people, 2.70%

* Approximation only. Some reports may have incomplete information.

Do you take Latuda and have Agranulocytosis?

- Check whether Agranulocytosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Latuda:

Latuda (21,543 reports)

Agranulocytosis treatments and more:

Agranulocytosis (213,267 reports)

Browse all side effects of Latuda:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Agranulocytosis:

Agranulocytosis (2,327 drugs)

Browse all the conditions that are associated with Agranulocytosis:

Agranulocytosis (3,591 conditions)

Related publications that referenced our studies

Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .
Reddy, B., Das, S., & Ali, M. , "A Case of Hypersexuality Probably Associated With Lurasidone", Journal of clinical psychopharmacology, 2018 Jan .
Sood S, "Neutropenia with Multiple Antipsychotics Including Dose Dependent Neutropenia with Lurasidone", Clinical Psychopharmacology and Neuroscience, 2017 Jan .
Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .
Reddy, B., Das, S., & Ali, M. , "A Case of Hypersexuality Probably Associated With Lurasidone", Journal of clinical psychopharmacology, 2018 Jan .
Sood S, "Neutropenia with Multiple Antipsychotics Including Dose Dependent Neutropenia with Lurasidone", Clinical Psychopharmacology and Neuroscience, 2017 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on lurasidone hydrochloride (the active ingredients of Latuda) and Latuda (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.